Aptean offers Onyx CRM customers Experian Data Quality address and email validation
InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action
Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs
Oregan Networks Enters Data-Driven Personalised Programming Market
Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative
Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.
The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.
Health-care stocks are on a tear as demand slowly returns.